Newborn metabolic screening: the heel prick test explained

Newborn · Health · Reviewed 20 June 2026 · All articles

In the first day or two after your baby is born, a nurse or midwife will gently prick the heel of your newborn, collect a few drops of blood onto a special filter-paper card, and send it to a laboratory. This small act, sometimes called the heel prick test or newborn blood spot screening, is one of the most powerful public health tools available for protecting babies from serious conditions that otherwise show no symptoms until real harm has already begun. Understanding what is being tested, why timing matters, and what happens if results are unusual can help you feel informed and calm throughout the process.

What is the heel prick test?

The heel prick test is the informal name for newborn blood spot screening. A small lancet device creates a tiny puncture in the outer edge of your baby's heel, and blood is collected onto a filter-paper card printed with circles. This card, sometimes called a Guthrie card after the physician Robert Guthrie who pioneered early newborn PKU screening in the 1960s, is sent to a state or regional laboratory for analysis.

The test is voluntary in most jurisdictions, but acceptance rates are extremely high because the benefit is clear: many of the conditions on the panel have no visible symptoms in the newborn period, yet catching them early and starting treatment quickly can mean the difference between a child thriving and a child facing serious disability or, in the most severe cases, death. Early detection gives families and clinicians a head start before the disease has a chance to cause lasting damage.

In the United States, newborn screening programs are operated at the state level, so the exact number of conditions tested can vary. However, a federal advisory committee called the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) maintains a national framework known as the Recommended Uniform Screening Panel (RUSP), which guides states toward a consistent, evidence-based minimum set of conditions.

Why newborn screening matters: catching conditions early

Most of the conditions on the newborn screening panel are metabolic or genetic disorders that affect how the body processes nutrients, or how certain organs function. In a typical newborn, none of these conditions announce themselves through obvious signs. A baby with phenylketonuria (PKU) looks completely healthy at birth. A newborn with congenital hypothyroidism feeds and sleeps like any other baby. The damage, however, is already beginning.

In PKU, for example, the body cannot break down an amino acid called phenylalanine. Without a low-phenylalanine diet started in the first weeks of life, phenylalanine builds up in the blood and causes progressive brain damage and intellectual disability. With early dietary management, children with PKU now routinely achieve normal cognitive development.

Congenital hypothyroidism is equally instructive. A baby born without enough thyroid function will fall behind in brain development and growth unless thyroid hormone replacement begins promptly. Before newborn screening existed, many of these children were not diagnosed until developmental delays became obvious, often too late for a full recovery. Now, thyroid replacement is started within days of the positive screen, and outcomes are dramatically better.

This is the core logic behind population-wide newborn screening: most babies screened will have entirely normal results, but for the small number who screen positive, the speed of the intervention directly determines their future health. The cost of running the test for every baby is far outweighed by the lifelong cost of treating preventable complications.

The screening panel: what conditions are tested

The RUSP as of 2025 includes more than 60 conditions across several categories. Here is an overview of the main groups.

Amino acid disorders

These are conditions where the body cannot process one or more amino acids normally. Phenylketonuria (PKU) is the best-known, but the panel also covers maple syrup urine disease (MSUD), homocystinuria, tyrosinemia, and several others. Untreated, these disorders lead to neurological damage. Many are managed with specialised formulas and dietary restrictions.

Fatty acid oxidation disorders

These conditions affect the body's ability to convert fat into energy, especially during periods of fasting or illness. Medium-chain acyl-CoA dehydrogenase deficiency (MCAD) is the most common. Babies with MCAD can experience life-threatening metabolic crises triggered by missed feeds or common illnesses. Early identification allows families to follow safe-feeding schedules and act quickly during illness.

Organic acid disorders

This group includes conditions such as methylmalonic acidemia (MMA), propionic acidemia, and isovaleric acidemia. These involve defects in the breakdown of certain amino acids and fatty acids, causing harmful organic acids to accumulate. Without management, affected babies can develop severe metabolic acidosis, often in the first days of life.

Endocrine disorders

Congenital hypothyroidism, caused by an absent or underactive thyroid gland, is screened in every jurisdiction. Congenital adrenal hyperplasia (CAH), which disrupts cortisol and aldosterone production and can cause dangerous salt-wasting crises in newborns, is also universally screened.

Hemoglobin disorders

Sickle cell disease and other hemoglobin variants are detected through the newborn blood spot. Early identification allows prophylactic penicillin to start before two months of age, dramatically reducing the risk of life-threatening bacterial infections that disproportionately affect babies with sickle cell disease. The screen also identifies other hemoglobinopathies that benefit from early management and genetic counselling for the family.

Cystic fibrosis

Cystic fibrosis (CF) is a genetic condition affecting mucus production in the lungs and digestive system. The newborn screen typically measures immunoreactive trypsinogen (IRT), a pancreatic marker. If IRT is elevated, a DNA analysis for common CFTR variants follows. Early CF identification allows nutritional support to begin promptly and ensures the family connects with a CF specialist team before the first pulmonary complications arise.

Severe combined immunodeficiency (SCID) and spinal muscular atrophy (SMA)

These two conditions are among the more recent additions to the RUSP. SCID is a group of disorders in which babies are born without a functioning immune system. Without a stem cell transplant in the first months of life, a SCID-affected baby is at risk of fatal infection from any ordinary germ. SMA causes progressive muscle weakness; the earlier treatment begins, the better the neurological outcome. The addition of both conditions to universal screening has transformed outcomes in a very short time.

Hearing screening

While separate from the blood spot, many newborn screening programs also include a hearing screen using otoacoustic emissions or auditory brainstem response testing. Hearing loss identified and supported early is associated with much stronger language development than hearing loss picked up later.

Timing and how the test is done

The optimal window for the heel prick blood spot test is 24 to 48 hours after birth. This timing is carefully chosen. For conditions such as PKU, the baby must have received protein-containing feeds for long enough that abnormal metabolites have had a chance to accumulate and become detectable. Testing too early produces a higher rate of false-negative results. Testing after 48 hours is still valuable, though programs aim to capture results before hospital discharge.

If your baby is born at home or discharged before 24 hours, your midwife or community health nurse will arrange the test in the first week. For babies admitted to a neonatal intensive care unit (NICU), the test may be done at a different time depending on the baby's condition, with a repeat test typically scheduled after the baby is medically stable or when feeds are well established.

Premature babies often receive an initial screen and then a second screen at a corrected age, because some metabolic markers are not reliable in very preterm infants until their physiology has matured further. NICU teams are experienced with this protocol and will guide families through the timing.

How blood spots are collected and processed

Before the prick, a nurse warms the heel using a warm compress or heel warmer for several minutes. Warmth dilates the capillaries and makes blood flow freely, which reduces the number of pricks needed and improves sample quality. The outer edge of the heel is used rather than the back or the arch, to avoid the calcaneus (heel bone).

A small, spring-loaded lancet device creates a puncture of controlled depth, typically less than 2.4 mm for term newborns. The first drop of blood is wiped away to avoid contamination, and subsequent drops are allowed to fall directly onto the circles printed on the filter-paper card. The circles must be filled completely and from one side only. Squeezing the heel vigorously is avoided because this can haemolyse (break down) the blood cells and compromise results.

The card is allowed to dry horizontally at room temperature, away from direct heat and sunlight, usually for at least three hours. Once dry, it is sealed in an envelope and sent to the state laboratory. Most programs aim to receive the card within 24 hours of collection, though courier schedules vary.

At the laboratory, small punches are taken from each blood spot and analysed using tandem mass spectrometry (MS/MS) for most metabolic conditions, enzyme activity assays for specific disorders, immunoassays for hormones such as TSH (thyroid-stimulating hormone), and DNA-based methods for CF CFTR variants and SCID T-cell receptor excision circle (TREC) counts. The combination of these technologies means that a single small blood spot can yield results for all conditions on the panel simultaneously.

Getting your results: what to expect

In most programs, normal results are reported to the birth hospital, your pediatrician, or your midwife within one to two weeks of the sample being received. Many parents never receive a direct communication because normal results are simply filed in the medical record. If you want to confirm that your baby's results were normal, ask your pediatrician at the first well-baby visit.

If a result is outside the normal range for any condition, the laboratory contacts your baby's healthcare provider directly, usually by phone, and the provider then contacts you. How quickly this happens depends on the urgency of the finding: some conditions require same-day action, while others allow a few days for a follow-up appointment to be arranged. Programs with modern electronic reporting systems can now deliver results within 24 to 48 hours of sample receipt.

Most states have a follow-up coordinator embedded in their newborn screening program. This person's job is to ensure that every screen-positive baby receives timely specialist evaluation. If you receive a call about a positive screen, you can ask to speak with the program's follow-up coordinator, who can explain the specific condition, the recommended next steps, and what specialist team your baby should see.

Understanding a positive screen: screen positive versus diagnosis

This distinction is one of the most important things parents can understand before they receive any results. A screen-positive result (also called an out-of-range or abnormal result) means that one measurement in your baby's blood spot was outside the normal range. It is a signal to investigate further. It is not a diagnosis.

Newborn screening is designed to be highly sensitive: it is calibrated to catch essentially every true case of each condition. The trade-off is that this sensitivity produces a number of false positives, babies who screen positive but, after confirmatory testing, turn out not to have the condition. For many conditions on the panel, the majority of screen-positive babies do not have the disease. This is expected and is built into the system.

Confirmatory tests are different from screening tests. They are more precise, often measure a different analyte, and are designed to distinguish true disease from the false alarm of a borderline screen. Examples include plasma amino acid quantification for amino acid disorders, acylcarnitine profiling for fatty acid oxidation defects, serum free thyroxine (T4) and TSH measurement for hypothyroidism, and sweat chloride testing for cystic fibrosis. DNA sequencing may follow if initial confirmatory tests are ambiguous.

While waiting for confirmatory results, your care team may recommend starting some precautionary measures, for example avoiding long gaps between feeds in a baby with a possible fatty acid oxidation disorder, or temporarily adjusting feeds for a possible amino acid disorder. These steps are precautionary, not confirmatory diagnoses, and will be reviewed once the full picture is clear.

If you are facing a positive screen right now, the most helpful framing is this: the system is doing exactly what it was designed to do. Your baby was caught in the safety net. The next step is to find out whether the net caught a real problem or a shadow. Either way, your baby is being watched closely, and that is the right place to be.

Frequently asked questions

When is the heel prick test done after birth?

The heel prick test is ideally done between 24 and 48 hours after birth. Testing before 24 hours can produce false results for some conditions, such as PKU, because the baby has not yet had enough time to process protein from feeds. If your baby is discharged very early, the test may be arranged through your midwife or pediatrician in the first week.

Does the heel prick test hurt my baby?

The small lancet prick causes brief discomfort. Most hospitals recommend feeding or skin-to-skin contact during the procedure, which research shows significantly reduces pain response. The heel is warmed beforehand to improve blood flow, and the whole process takes just a few minutes. Any redness or soreness at the prick site usually resolves within a day.

What does a positive newborn screen result mean?

A screen-positive result means the initial test found a value outside the normal range for one or more conditions. It is not a diagnosis. Most screen-positive babies turn out not to have the condition after follow-up confirmatory testing. Your care team will contact you promptly to arrange further blood tests, urine tests, or specialist review. Acting quickly on a positive screen is important, but try to wait for confirmatory results before drawing conclusions.

What happens if my baby misses the newborn screen?

If the sample is missed, collected too early, or the results are inconclusive, a repeat test will be arranged. Screening can still be done in the first weeks of life and remains valuable. Let your pediatrician or midwife know if you are unsure whether your baby has been screened, and they will check the record and arrange a repeat if needed.

Track your newborn's health checks in Cubby

Cubby helps you log your baby's appointments, vaccines, and health milestones in one private place. Set reminders for follow-up visits, keep notes after each check, and share a clear summary with your pediatrician. Your data stays with you, always.

Try Cubby free

Trusted sources